ライフサイエンスコーパス: intracoronary

1 tervention (n=80) were randomized to receive intracoronary (10 mL) sodium nitrite (1.8 mumol) or NaCl

2 Under control conditions (intracoronary 5% dextrose in water), atrial-pacing tachy

3 Patients randomized to intracoronary abciximab also had a significant reduction

4 improve outcomes after primary PCI are bolus intracoronary abciximab and manual aspiration thrombecto

5 The intracoronary abciximab bolus did not reduce the primary

6 Administration of an intracoronary abciximab bolus during primary percutaneou

7 Patients randomized to intracoronary abciximab compared with no abciximab had a

8 y reduced in diabetic patients randomized to intracoronary abciximab compared with those randomized t

9 open-label, 2 x 2 factorial design to bolus intracoronary abciximab delivered locally at the infarct

10 t 30 days was significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion

11 icantly less congestive heart failure in the intracoronary abciximab group.

12 c patients with STEMI, the administration of intracoronary abciximab improved the effectiveness of pr

13 resent in 181 and 172 patients randomized to intracoronary abciximab vs no abciximab, respectively, a

14 e epicardial vasoconstriction in response to intracoronary acetylcholine (-19+/-2% versus -14+/-1% ch

15 -four patients of the latter (86%) underwent intracoronary acetylcholine (ACH) testing, which elicite

16 cular resistance, and vasomotor responses to intracoronary acetylcholine (vasospasm provocation) was

17 However, provocation tests using intracoronary acetylcholine administration are rarely pe

18 The intracoronary acetylcholine provocation test is a safe t

19 angiographic characteristics, and safety of intracoronary acetylcholine provocation testing in white

20 The intracoronary acetylcholine provocation testing was perf

21 ACS patients without culprit lesion, in whom intracoronary acetylcholine provocation was performed, h

22 dial endothelial functional assessment using intracoronary acetylcholine; second, epicardial severity

23 mized (3:1 ratio) to receive 1 of 5 doses of intracoronary Ad5.hAC6 or placebo.

24 Thirty-nine patients received intracoronary adeno-associated virus type 1/sarcoplasmic

25 coronary flow reserve was examined by use of intracoronary adenosine and nitroglycerin.

26 d baseline coronary flow reserve (CFR) after intracoronary adenosine in 189 women referred to evaluat

27 endent) coronary flow reserve in response to intracoronary adenosine were evaluated.

28 y measurements were performed at rest, after intracoronary adenosine, and during increasing infusion

29 ty was not different between intravenous and intracoronary administration (1.47% versus 1.33%; P=0.5)

30 Intracoronary administration of Ad5.hAC6 (3.2 x 109 to 1

31 Preclinical studies with intracoronary administration of Ad5FGF-4 (alferminogene

32 The modest effects of clinical studies using intracoronary administration of autologous bone marrow-d

33 Intracoronary administration of autologous bone marrow-d

34 Intracoronary administration of autologous CDCs did not

35 hronic heart failure, shock wave-facilitated intracoronary administration of BMCs vs shock wave treat

36 Intracoronary administration of CDCs has been demonstrat

37 Intracoronary administration of CPCs in the setting of a

38 model of AMI relevant to the human disease, intracoronary administration of IGF-1/HGF is a practical

39 day outcome in 775 consecutive procedures of intracoronary administration of progenitor cells using t

40 p, n=9) were compared with animals receiving intracoronary AdvEGFP (2x10(12) vp, n=6).

41 d regional function before and 30 days after intracoronary AdvFGF-5 (2x10(12) vp, n=9) were compared

42 hodology, we compared the efficacy of global intracoronary allogeneic MSCs (icMSCs, approximately 35x

43 4 to 6 h, adjunctive treatment with low-dose intracoronary alteplase during primary percutaneous coro

44 hin 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percuta

45 of a therapeutic strategy involving low-dose intracoronary alteplase infused early after coronary rep

46 Intracoronary alteplase may be harmful for this subgroup

47 tematically compared FFR measurements during intracoronary and intravenous application of adenosine a

48 52) did not differ significantly between the intracoronary and the intravenous abciximab groups.

49 In an open-label blinded study, we compared intracoronary and transendocardial CD34(+) cell transpla

50 Intracoronary angiotensin-converting enzyme inhibitors h

51 c reperfusion was performed for 90 min using intracoronary AO.

52 Limited data validate the intracoronary application of adenosine against standard

53 Reported discomfort after intracoronary application was significantly lower compar

54 ee cycles of 10/10 min r-I/R by percutaneous intracoronary balloon inflation/deflation in the mid lef

55 tions were by immunoblotting in systemic and intracoronary blood from independent cohorts of patients

56 ry cells in the infarct border zone, whereas intracoronary BM cell injection provided more homogeneou

57 of NT-proBNP serum levels at 4 months after intracoronary BMC administration in patients with ICM, s

58 ntial impairment of kidney function received intracoronary BMC administration.

59 cell retention and determine the response to intracoronary BMC application in patients with ICM.

60 istics than on whether the patient underwent intracoronary BMC transplantation.

61 ated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the

62 ention, 120 patients were randomized to a 1) intracoronary BMMC injection; 2) mobilization with G-CSF

63 intravenous infusion versus 23 +/- 14 s for intracoronary bolus administration of adenosine (P < 0.0

64 Intracoronary bolus administration of eptifibatide durin

65 Intracoronary bolus administration of eptifibatide may r

66 Two FFR measurements were performed during intracoronary bolus injection (40 mug for the right and

67 Intracoronary bolus injection of adenosine (40 mug for t

68 aseline and maximal hyperemia, induced by an intracoronary bolus of adenosine (20-40 microg).

69 Intracoronary bolus of apelin-36 increased coronary bloo

70 ly assigned 40 patients to receive either an intracoronary bolus of enalaprilat (50 mug) or placebo b

71 Intracoronary cardiospheres are also remarkably effectiv

72 Importantly, intracoronary cardiospheres decreased left ventricular e

73 We investigated long-term effects of intracoronary CD34+ cell transplantation in dilated card

74 erform a meta-analysis of clinical trials on intracoronary cell therapy after acute myocardial infarc

75 We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarc

76 Intracoronary cell therapy continues to be evaluated in

77 Intracoronary cell therapy following percutaneous corona

78 Subjects that received intracoronary cell therapy had a significant improvement

79 zed trials targeted to address the impact of intracoronary cell therapy on overall and event-free lon

80 databases for controlled trials reporting on intracoronary cell therapy performed in patients with a

81 ls in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms

82 Intracoronary cell therapy was also associated with a no

83 hearts of three different mammalian species, intracoronary chloroquine perfusion reduced fibrillatory

84 ased only in diabetic patients randomized to intracoronary compared with intravenous abciximab (54.4;

85 nt study was undertaken to determine whether intracoronary CSCs are beneficial in a porcine model of

86 farction, the dose-response relationship for intracoronary CSCs is flat.

87 etrospective multicentric registry and Mainz Intracoronary Database.

88 Initially, intracoronary delivery conditions were optimized in 20 s

89 Ex vivo intracoronary delivery of adenovirus-mediated gene trans

90 ate the safety, feasibility, and efficacy of intracoronary delivery of allogeneic human cardiac stem

91 sed the safety, feasibility, and efficacy of intracoronary delivery of allogeneic MPCs directly after

92 test, for the first time, the feasibility of intracoronary delivery of an innovative, injectable bioa

93 Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuc

94 Harvesting, processing, and intracoronary delivery of BMCs in this setting was feasi

95 Intracoronary delivery of BNP116.I-1c was safe and impro

96 Intracoronary delivery of c-kit-positive human cardiac s

97 luating the safety and efficacy of optimized intracoronary delivery of cardiospheres in a porcine mod

98 Intracoronary delivery of cardiospheres is safe.

99 Intracoronary delivery of CDCs in a preclinical model of

100 rgitation induction, pigs were randomized to intracoronary delivery of either BNP116.I-1c (n = 6) or

101 after myocardial infarction, pigs underwent intracoronary delivery of either recombinant adeno-assoc

102 At 2 months, pigs underwent intracoronary delivery of either recombinant adeno-assoc

103 Intracoronary delivery of endothelial progenitor cells (

104 rdial blood flow, to quantify the effects of intracoronary delivery of recombinant TIMP-3 (rTIMP-3) o

105 o evaluate therapeutic interventions such as intracoronary delivery of rTIMP-3 for reduction of I/R i

106 This first-in-man pilot study shows that intracoronary deployment of an IK-5001 scaffold is feasi

107 Intracoronary deployment of BCM 2 to 5 days after succes

108 efined as the successful manipulation of the intracoronary devices using the robotic system only.

109 onary pulse wave analysis, we calculated the intracoronary diastolic suction wave (the principal acce

110 d troponin, microemboli can be visualized by intracoronary Doppler and the resulting microinfarcts by

111 three patients were studied; in 24 patients, intracoronary Doppler flow velocity measurements were pe

112 y disease, and may be accurately assessed by intracoronary Doppler flow velocity measurements.

113 primary percutaneous coronary intervention, intracoronary Doppler flow velocity was measured in the

114 s calculated from flow velocity, measured by intracoronary Doppler, and luminal diameter, measured by

115 Of these, 5 received 5 biweekly intracoronary doxorubicin doses (0.45 mg/kg/injection) a

116 u) responses were assessed during continuous intracoronary drug infusion in sinus rhythm followed by

117 There was a decrease in intracoronary ECG ST-elevation during RCA occlusion from

118 erve during vessel patency, the quantitative intracoronary ECG ST-segment elevation, and angina pecto

119 end point was the quantitatively determined intracoronary ECG ST-segment elevation.

120 Intracoronary ECG ST-segment elevations were significant

121 the second and third inflations, both on the intracoronary electrocardiogram (ECG) (21.0 +/- 2.8 mm v

122 Intracoronary enalaprilat improves coronary microvascula

123 This study investigated the influence of intracoronary enalaprilat on coronary microvascular func

124 l, or other adverse findings attributable to intracoronary eptifibatide.

125 This emphasizes the requirement of intracoronary flow assessment in addition to coronary pr

126 including quantitative coronary angiography, intracoronary flow velocity probes, and pharmacologic st

127 overexpression in pig hearts was achieved by intracoronary gene delivery of adenovirus in the 3 main

128 ression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function,

129 ndocardial group (+8.1 +/- 4.3%) than in the intracoronary group (+4.2 +/- 2.3%, P=0.03).

130 ndocardial group (19.2 +/- 4.8%) than in the intracoronary group (4.4 +/- 1.2%, P<0.01).

131 In the intracoronary group, cells were injected intracoronarily

132 endocardial group versus +86 +/- 13 m in the intracoronary group, P=0.03) and N-terminal pro-brain na

133 rdial group versus 103 +/- 27 x 10(6) in the intracoronary group, P=0.62).

134 e index, compared with established hyperemic intracoronary hemodynamic parameters, because achievemen

135 Intracoronary hyperoxemic reperfusion was safe and well

136 was tested by coronary dilation response to intracoronary (IC) acetylcholine and IC nitroglycerin.

137 rctions, few high-risk plaques identified by intracoronary imaging actually result in future major ad

138 Intracoronary imaging is critical to identify the mechan

139 The highest-resolution intracoronary imaging modality, optical coherence tomogr

140 Intracoronary imaging provides unique insights to unrave

141 and coronary blood flow quantification, and intracoronary imaging to detect early changes in the ves

142 onsible for MACE and improves the ability of intracoronary imaging to predict events.

143 vention is also due to important advances in intracoronary imaging, and adjunct pharmacotherapy-each

144 An algorithmic approach, guided by intracoronary imaging, for the treatment of DES-ISR, is

145 ilability and application of high-resolution intracoronary imaging.

146 Intracoronary implantation of the EES is associated with

147 of heart failure, overexpression of I-1c by intracoronary in vivo gene transfer preserved cardiac fu

148 ogic analysis was used to confirm successful intracoronary infiltration of MGd and trypan blue within

149 million autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) afte

150 AntimiR-21 (10 mg) was applied by intracoronary infusion at days 5 and 19 after the injury

151 injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement.

152 1.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement.

153 IE) was delivered into cardiac allografts by intracoronary infusion ex vivo.

154 ioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in patients with left ventricular

155 res may be viable therapeutic candidates for intracoronary infusion in selected myocardial disorders.

156 cardial injection, intravenous infusion, and intracoronary infusion indicated no improvement.

157 and web-response system, to receive a single intracoronary infusion of 1 x 10(13) DNase-resistant par

158 d 2-3 weeks later were randomized to receive intracoronary infusion of 12.5x10(6) mismatched allogene

159 Intracoronary infusion of 150 x 10(6) autologous BMCs (t

160 Intracoronary infusion of 150 x 106 BMCs or placebo (ran

161 33 severe) were randomized to receive either intracoronary infusion of 3 incremental doses of eMSC or

162 t failure therapy were randomized to receive intracoronary infusion of AAV1/SERCA2a in 1 of 3 doses (

163 After a single intracoronary infusion of AAV1/SERCA2a in patients with

164 Intracoronary infusion of allogeneic MPCs is safe, feasi

165 dysfunction following reperfusion with PCI, intracoronary infusion of autologous BMCs vs intracorona

166 However, the responses after intracoronary infusion of autologous bone marrow-derived

167 INTERPRETATION: We show intracoronary infusion of autologous CDCs after myocardi

168 Intracoronary infusion of autologous CSCs improves regio

169 They suggest that intracoronary infusion of autologous CSCs is effective i

170 LV dysfunction after successful reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days o

171 might be recommended as an anticoagulant for intracoronary infusion of BMCs for cell therapy after ca

172 ment were randomized to receive double-blind intracoronary infusion of BMCs or placebo, and patients

173 tients receiving placebo shock wave received intracoronary infusion of BMCs.

174 Intracoronary infusion of BMMNC is safe, but does not en

175 RATIONALE: Intracoronary infusion of bone marrow (BM) mononuclear c

176 ction induced by ischemia/reperfusion before intracoronary infusion of CDCexo, inert fibroblast exoso

177 The intracoronary infusion of cells imposes the potential ri

178 vestigate the efficacy of different doses of intracoronary infusion of eMSC in a porcine model of acu

179 g coronary angioplasty were randomized to an intracoronary infusion of enalaprilat or placebo, follow

180 In an isolated heart model, intracoronary infusion of IL-18BP MSCs before ischemia i

181 sel stenosis were studied at rest and during intracoronary infusion of nitroglycerin (0.3 to 0.6 micr

182 Intracoronary infusion of progenitor cells can be perfor

183 ion, pigs with I/R were randomly assigned to intracoronary infusion of rTIMP-3 (1.0 mg/kg; n=5) or sa

184 sine-induced maximal hyperemia as reference, intracoronary infusion of saline at rates of 5, 10, 15,

185 Intracoronary infusion of saline at room temperature thr

186 metric coronary blood flow, we observed that intracoronary infusion of saline increased coronary flow

187 h angiographically normal coronary arteries, intracoronary infusion of SMTC (0.625 micromol/min) redu

188 nary occlusion/reperfusion, rats received an intracoronary infusion of vehicle or enhanced green fluo

189 796863), the authors assessed the effects of intracoronary infusion with bone marrow-derived mononucl

190 al in the setting of an old MI when given by intracoronary infusion, the most widely applicable thera

191 , have been associated with infarction after intracoronary infusion.

192 ells; N=78) or (2) diluent alone (N=83), via intracoronary infusion.

193 ing was performed after consecutive 5-minute intracoronary infusions (vehicle solution, 0.30 mug/min

194 change in coronary blood flow in response to intracoronary infusions of acetylcholine during diagnost

195 ardiomyopathy, 20 were randomized to receive intracoronary injection and 20 received transendocardial

196 Dynamic tracking during intracoronary injection of (18)F-FDG-labeled CPC is feas

197 Intracoronary injection of AAV9.I-1c prevented further d

198 Intracoronary injection of autologous BMNCs does not imp

199 35, and optimized therapy were randomized to intracoronary injection of autologous BMNCs or placebo.

200 ricular tachycardia for the initial 14 days; intracoronary injection of BM cells and intramyocardial

201 Both intramyocardial and intracoronary injection of BM cells demonstrated similar

202 though various approaches have been studied, intracoronary injection of bone marrow autologous mononu

203 We investigated whether intracoronary injection of nitrite during primary percut

204 rdial repair through a clinically applicable intracoronary injection protocol in a pig model of myoca

205 ulating progenitor cell (CPC) therapy during intracoronary injection, using a porcine model of acute

206 udy has shown that liposome-mediated ex vivo intracoronary interleukin (IL)-4 and IL-10 combined gene

207 cell delivery have been reported, including intracoronary, intramyocardial, intravenous, and epicard

208 Intracoronary levosimendan (3.75 and 12.5 microg/min for

209 bing findings suggestive of angiographic and intracoronary manifestations of coronary FMD.

210 Using intracoronary measurements, 91 coronaries (78 patients)

211 n emission tomography and its interplay with intracoronary measurements.

212 In one study, dogs with intracoronary microembolization-induced HF were randomiz

213 rcts were created in Yorkshire pigs (n=6) by intracoronary microsphere injection.

214 c hibernating myocardium received autologous intracoronary MSCs (icMSCs; approximately 44 x10(6) cell

215 uvastatin 40 mg for 8-12 weeks and underwent intracoronary multimodality imaging of an obstructive no

216 tervention for a culprit lesion, followed by intracoronary multimodality imaging, including optical c

217 In this study, intracoronary near-infrared spectroscopy (NIRS) was used

218 determine the long-term prognostic value of intracoronary NIRS as assessed in a nonculprit vessel in

219 vasomotor reactivity after administration of intracoronary nitrate.

220 he stenosis were measured at baseline, after intracoronary nitrates, and after stent PCI.

221 ng that a phase III clinical trial assessing intracoronary nitrite administration as an adjunct to pe

222 In this phase II study, intracoronary nitrite infusion did not alter infarct siz

223 nderwent coronary diameter measurement after intracoronary nitroglycerin injection 5, 20, and 35 mm d

224 pacing for endothelium-dependent cases; and intracoronary nitroglycerin injection for endothelium-in

225 However, administration of cells requires intracoronary or intracardiac instrumentation, which is

226 IDA STEMI trial randomized 2,065 patients to intracoronary or intravenous abciximab and found similar

227 ents with and without diabetes randomized to intracoronary or intravenous abciximab bolus at the time

228 coronary syndrome were randomized to either intracoronary or intravenous bolus administration of ept

229 egment shift during inflations on either the intracoronary or the surface ECG.

230 ing utilized to further our understanding of intracoronary pathology and the effects of therapies bot

231 s performed to calculate aortic (Pa), distal intracoronary (Pd), and reservoir (Pr) pressure at basel

232 stable coronary artery disease who underwent intracoronary physiological evaluation of >/= 1 coronary

233 of functional coronary lesion severity using intracoronary physiological parameters such as coronary

234 intracoronary infusion of autologous BMCs vs intracoronary placebo infusion, 2 to 3 weeks after PCI,

235 ct of short-term intensive statin therapy on intracoronary plaque lipid content.

236 mbus aspirate analysis showed persistence of intracoronary polymer fragments in case 1.

237 l to the stenosis; in part 2 (118 stenoses), intracoronary pressure alone was measured.

238 Simultaneous intracoronary pressure and flow velocity recordings were

239 In 51 vessels, intracoronary pressure and flow velocity was measured di

240 Intracoronary pressure and flow velocity were measured a

241 In part 1 (39 stenoses), intracoronary pressure and flow velocity were measured d

242 Intracoronary pressure and flow velocity were measured i

243 Intracoronary pressure and flow velocity were simultaneo

244 Small drifts in intracoronary pressure measurements (+/-2 mm Hg) can aff

245 for the use of FFR during PCI and shows that intracoronary pressure wire guidance confers prognostic

246 Intracoronary pressure wire measurement of fractional fl

247 Immediately after successful PCI, intracoronary pressure-flow measurements were performed

248 lysis identified a wave-free period in which intracoronary resistance at rest is similar in variabili

249 Intracoronary resistance is naturally constant and minim

250 f animals were not transplanted but received intracoronary rIFN-gamma infusion into the native heart.

251 of autologous CD34(+) cells delivered via an intracoronary route after recent myocardial infarction i

252 oth P-selectin and ICAM-1 via the retrograde intracoronary route could be a promising new strategy fo

253 However, the more desirable intracoronary route has been assumed to be unsafe for ca

254 ardial biopsy specimens were infused via the intracoronary route in 17 patients with left ventricular

255 peptide, and exercise capacity compared with intracoronary route.

256 ch arrhythmias may be prevented by using the intracoronary route.

257 her a direct intramyocardial or a retrograde intracoronary route.

258 icle solution, 0.30 mug/min and 0.60 mug/min intracoronary salbutamol) to measure changes in segmenta

259 Intracoronary saline given on top of an intravenous infu

260 Intracoronary saline infusion did not affect blood press

261 thoracic echocardiography during a prolonged intracoronary saline infusion.

262 ngle vessel coronary artery disease and mean intracoronary shear estimates at 2935 seconds(-1) (peak

263 mic minipigs (n=5) were instrumented with an intracoronary shear-modifying stent (SMS).

264 Intracoronary stem cell transplantation may be associate

265 ificant coronary artery disease receiving an intracoronary stent between April 2004 and December 2007

266 onary syndromes, 11 289 (61%) had at least 1 intracoronary stent.

267 The aim of the ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen-ASpiri

268 el in the setting of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid

269 nt Intervention Triage Strategy (ACUITY) and Intracoronary Stenting and Antithrombotic Regimen: Rapid

270 The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid

271 being challenged by recent clinical trials (Intracoronary Stenting and Antithrombotic Regimen: Rapid

272 : Rapid Early Action for Coronary Treatment, Intracoronary Stenting and Antithrombotic Regimen: Rapid

273 Intracoronary stenting can improve procedural success an

274 atients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a

275 l methodologies confirmed the finding of the Intracoronary Stenting With Antithrombotic Regimen Cooli

276 only, small, randomized clinical trial, the Intracoronary Stenting With Antithrombotic Regimen Cooli

277 patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivarox

278 ervention (PCI), which involves placement of intracoronary stents in most patients, is a less invasiv

279 Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet r

280 tensive platelet inhibition in patients with intracoronary stents.

281 idly become a preferred modality for imaging intracoronary structures such as coronary plaques and co

282 had no effect on increases in flow evoked by intracoronary substance P (20 pmol/min).

283 ents who might benefit from further adjuvant intracoronary therapies, such as thrombolysis, vasodilat

284 r development of molecular MR imaging-guided intracoronary therapy.

285 elements in patients who succumbed to fatal intracoronary thrombosis.

286 atient population with a high probability of intracoronary thrombosis.

287 Persistent intracoronary thrombus after plaque rupture is associate

288 Routine intracoronary thrombus aspiration before primary percuta

289 The clinical effect of routine intracoronary thrombus aspiration before primary percuta

290 Ten patients were found to have intracoronary thrombus on x-ray coronary angiography (le

291 tery disease (atherosclerotic plaques and/or intracoronary thrombus).

292 motor tone after CTO reopening suggests that intracoronary ultrasound assessment is of paramount impo

293 Intracoronary ultrasounds failed to show changes of the

294 13 patients, distal vessels were assessed by intracoronary ultrasounds.

295 ular tachycardia, which was only resolved by intracoronary vasodilator injection.

296 patients to date demonstrates no benefit of intracoronary versus intravenous abciximab administratio

297 udy was to investigate potential benefits of intracoronary versus intravenous abciximab bolus adminis

298 Among diabetic patients, intracoronary versus intravenous abciximab bolus was ass

299 tor occupancy was significantly greater with intracoronary versus intravenous administration: first b

300 yocardial infarction frame count (cTFC) with intracoronary versus intravenous administration: pre-PCI